Premium
Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy
Author(s) -
Zamani Parvin,
MomtaziBorojeni Amir Abbas,
Nik Maryam Ebrahimi,
Oskuee Reza Kazemi,
Sahebkar Amirhossein
Publication year - 2018
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26361
Subject(s) - immune system , liposome , immunotherapy , adjuvant , antigen , cancer immunotherapy , cationic liposome , cancer , immunopotentiator , medicine , active immunotherapy , immunology , cancer research , biology , genetic enhancement , biochemistry , gene
Cancer immunotherapy is one of the commonly used methods in the treatment of cancer. The aim of this approach is to strengthen or restore immune function for effective diagnosis of aberrant cells antigens. For this reason, cancer specific peptides or proteins are used as antigens to induce an immune response capable of removing cancer cells. Liposomal formulations are an important carrier system frequently used for delivery of antigen because the specific properties of this component such as lipid composition, charge, size, encapsulation of antigens, or adjuvants can be changed. Among different types of liposomal formulations, the use of cationic and pH‐sensitive nanoliposomes has been markedly increased for liposome‐based vaccines. In this review, we describe the properties of nanoliposomes as delivery systems for cancer immunotherapy.